Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

Stopped early

Conditions studied: Calciphylaxis

In brief

This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial).

Key facts

Study ID

NCT03319914

Run by

Hope Pharmaceuticals

People needed

5

Starts

2017-10-20

Expected to finish

2018-11-09

Last updated by the study team

2018-11-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previously enrolled as a patient in ST-001 CALISTA study
• Willing to provide written informed consent
• Willing and able to adhere to all study-related procedures
• Willing to authorize release of medical records
• Willing to authorize collection of medical data from health care providers
• Provide email, home address and phone number where he/she can be reached

You may not qualify if…

• Patient did not participate in ST-001 CALISTA study

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Veterans Administration Medical Center — Albany, New York, United States
• Cleveland Clinic — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.